Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

BACKGROUND: In the cetuximab after progression in KRAS wild-type colorectal cancer patients (CAPRI) trial patients with metastatic colorectal cancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-Fluorouracil, folinic acid, oxaliplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinelli, E, Cardone, C, Troiani, T, Normanno, N, Pisconti, S, Sforza, V, Bordonaro, A R, Rachiglio, A M, Lambiase, M, Latiano, T P, Modoni, G, Cordio, S, Giuliani, F, Biglietto, M, Montesarchio, V, Barone, C, Tonini, G, Cinieri, S, Febbraro, A, Rizzi, D, De Vita, F, Orditura, M, Colucci, G, Maiello, E, Ciardiello, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548975/
https://www.ncbi.nlm.nih.gov/pubmed/28848656
http://dx.doi.org/10.1136/esmoopen-2016-000086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548975/
https://www.ncbi.nlm.nih.gov/pubmed/28848656
http://dx.doi.org/10.1136/esmoopen-2016-000086

Ejemplares similares